MX2023001217A - Metodos de tratamiento de linfomas mutantes. - Google Patents
Metodos de tratamiento de linfomas mutantes.Info
- Publication number
- MX2023001217A MX2023001217A MX2023001217A MX2023001217A MX2023001217A MX 2023001217 A MX2023001217 A MX 2023001217A MX 2023001217 A MX2023001217 A MX 2023001217A MX 2023001217 A MX2023001217 A MX 2023001217A MX 2023001217 A MX2023001217 A MX 2023001217A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- lymphomas
- mutant
- treating
- treating mutant
- Prior art date
Links
- 206010025323 Lymphomas Diseases 0.000 title 1
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 abstract 1
- 239000001064 degrader Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063058891P | 2020-07-30 | 2020-07-30 | |
| US202063109854P | 2020-11-04 | 2020-11-04 | |
| US202163202242P | 2021-06-02 | 2021-06-02 | |
| PCT/US2021/071048 WO2022027058A1 (en) | 2020-07-30 | 2021-07-29 | Methods of treating mutant lymphomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001217A true MX2023001217A (es) | 2023-03-03 |
Family
ID=80036177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001217A MX2023001217A (es) | 2020-07-30 | 2021-07-29 | Metodos de tratamiento de linfomas mutantes. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11857535B2 (https=) |
| EP (1) | EP4188374A4 (https=) |
| JP (1) | JP2023536462A (https=) |
| KR (1) | KR20230044480A (https=) |
| CN (1) | CN116133692A (https=) |
| AU (1) | AU2021316053A1 (https=) |
| BR (1) | BR112023001638A2 (https=) |
| CA (1) | CA3187255A1 (https=) |
| IL (1) | IL300175A (https=) |
| MX (1) | MX2023001217A (https=) |
| PH (1) | PH12023550237A1 (https=) |
| TW (1) | TW202220653A (https=) |
| WO (1) | WO2022027058A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| US20240383887A1 (en) * | 2021-05-07 | 2024-11-21 | Kymera Therapeutics, Inc. | Deuterated irak degraders and uses thereof |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| CN115572768B (zh) * | 2022-11-04 | 2023-12-19 | 山东第一医科大学附属省立医院(山东省立医院) | 一种针对弥漫大b细胞淋巴瘤的预后评估及联合治疗 |
| WO2024148049A1 (en) * | 2023-01-04 | 2024-07-11 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| WO2024191788A1 (en) * | 2023-03-10 | 2024-09-19 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| CA2722159C (en) | 2008-04-24 | 2016-04-05 | Newlink Genetics Corporation | Substituted phenylimidazole compounds and their use as ido inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8921037B2 (en) | 2008-12-16 | 2014-12-30 | Bo Han | PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11542251B2 (en) * | 2018-02-14 | 2023-01-03 | Dana-Farber Cancer Institute, Inc. | IRAK degraders and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CN112969696B (zh) * | 2018-11-02 | 2024-06-11 | 达纳-法伯癌症研究公司 | 乙酰化书写器抑制剂的开发及其用途 |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| US20240383887A1 (en) * | 2021-05-07 | 2024-11-21 | Kymera Therapeutics, Inc. | Deuterated irak degraders and uses thereof |
-
2021
- 2021-07-29 CN CN202180062152.2A patent/CN116133692A/zh active Pending
- 2021-07-29 MX MX2023001217A patent/MX2023001217A/es unknown
- 2021-07-29 CA CA3187255A patent/CA3187255A1/en active Pending
- 2021-07-29 JP JP2023505922A patent/JP2023536462A/ja active Pending
- 2021-07-29 TW TW110127954A patent/TW202220653A/zh unknown
- 2021-07-29 IL IL300175A patent/IL300175A/en unknown
- 2021-07-29 PH PH1/2023/550237A patent/PH12023550237A1/en unknown
- 2021-07-29 BR BR112023001638A patent/BR112023001638A2/pt unknown
- 2021-07-29 US US17/444,015 patent/US11857535B2/en active Active
- 2021-07-29 EP EP21848959.9A patent/EP4188374A4/en not_active Withdrawn
- 2021-07-29 WO PCT/US2021/071048 patent/WO2022027058A1/en not_active Ceased
- 2021-07-29 KR KR1020237006759A patent/KR20230044480A/ko not_active Ceased
- 2021-07-29 AU AU2021316053A patent/AU2021316053A1/en not_active Abandoned
-
2023
- 2023-11-22 US US18/517,432 patent/US20240316004A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20240316004A1 (en) | 2024-09-26 |
| EP4188374A1 (en) | 2023-06-07 |
| US11857535B2 (en) | 2024-01-02 |
| IL300175A (en) | 2023-03-01 |
| JP2023536462A (ja) | 2023-08-25 |
| WO2022027058A1 (en) | 2022-02-03 |
| CN116133692A (zh) | 2023-05-16 |
| TW202220653A (zh) | 2022-06-01 |
| CA3187255A1 (en) | 2022-02-03 |
| EP4188374A4 (en) | 2024-08-14 |
| AU2021316053A1 (en) | 2023-03-02 |
| US20220054453A1 (en) | 2022-02-24 |
| KR20230044480A (ko) | 2023-04-04 |
| BR112023001638A2 (pt) | 2023-02-23 |
| PH12023550237A1 (en) | 2024-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12023550237A1 (en) | Methods of treating mutant lymphomas | |
| MX2023010429A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). | |
| MX2023009527A (es) | Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos. | |
| MX2023000081A (es) | Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor. | |
| MX2022009366A (es) | Compuestos y usos de estos. | |
| MX2023005160A (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma. | |
| PH12019502138A1 (en) | Compounds and compositions for treating hematological disorders | |
| PH12023500023A1 (en) | Cdk2 degraders and uses thereof | |
| PH12020500371A1 (en) | Spirocycle compounds and methods of making and using same | |
| MX2024001243A (es) | Composiciones y metodos para el tratamiento de melanoma. | |
| MX2025006782A (es) | Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos | |
| JOP20200023A1 (ar) | مركبات حلقية لولبية وطرق تصنيعها واستخدامها | |
| MX2023003973A (es) | Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos. | |
| WO2022082014A3 (en) | Skin targeted immunotolerance | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| PH12022550491A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
| MX2022000742A (es) | Metodo para disminuir los efectos adversos del interferon. | |
| ZA202201713B (en) | Improved treatment using eyp001 | |
| PH12022550118A1 (en) | Enzyme inhibitors | |
| PH12022550078A1 (en) | Enzyme inhibitors | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| MX2025002519A (es) | Derivados de piridazinona como degradadores de kat2 para el tratamiento de trastornos proliferativos | |
| WO2021041716A3 (en) | Therapeutic editing to treat cardiomyopathy | |
| IL279168B (en) | A process for the preparation of eribulin | |
| ZA202307787B (en) | Pretomanid amorphous form |